Clinical overview
Hypokalaemia may cause weakness, ileus, rhabdomyolysis and ventricular arrhythmia, particularly in people with heart disease or exposure to QT-prolonging medicines. The cause is often multifactorial and replacement is safest when the mechanism and magnesium status are considered.
Why this matters in practice
Hypokalaemia: Assessment, Replacement and Clinical Risk should be interpreted as part of a structured clinical assessment. The numerical result, symptom burden, rate of change, comorbidity, medicines and response to treatment all influence risk. A single threshold can support a decision, but it should not override clear evidence of physiological deterioration.
Physiology and pathophysiology
Low serum potassium can result from gastrointestinal or renal loss, inadequate intake or movement into cells. Insulin, beta-agonists and alkalosis promote intracellular uptake. Renal losses occur with diuretics, mineralocorticoid excess, tubular disorders and magnesium deficiency.
Measurement and pre-analytical checks
Confirm patient identity, specimen timing, units and the laboratory method. Review haemolysis, contamination, transport delay, sampling from an infusion line and other pre-analytical factors when the result is unexpected. Compare with previous measurements from the same laboratory where possible, because reference intervals and assay behaviour can differ.
Structured clinical assessment
Confirm severity, obtain an ECG when clinically indicated, review medicines and gastrointestinal losses, and measure magnesium, bicarbonate, glucose and renal function. Urinary potassium assessment can help distinguish renal from extrarenal loss. Replace orally when safe; intravenous replacement requires protocol-led concentration, rate and monitoring.
Interpretation in context
Interpret the value alongside observations, examination, fluid status, renal and liver function, acid-base data, medicines and relevant imaging or microbiology. Trend is often more informative than a single measurement. A modest abnormality that is changing rapidly may be more important than a stable, longstanding result outside the reference interval.
Special populations
Reference intervals and diagnostic performance may differ in pregnancy, children, older adults, critical illness, advanced kidney or liver disease and people with unusual body composition. Use population-specific guidance and specialist advice where the ordinary interpretation is unreliable. Do not transfer adult thresholds directly to paediatric or obstetric care.
Common pitfalls
Persistent hypokalaemia often reflects uncorrected magnesium deficiency or continued losses. Serum potassium may underestimate total deficit. Rapid intravenous administration can be dangerous, and dextrose-containing fluids may worsen intracellular shift.
Red flags and escalation
Arrhythmia, marked weakness, respiratory compromise, severe depletion, digoxin exposure or concurrent hypomagnesaemia warrants urgent monitored treatment.
Monitoring and follow-up
Set the repeat-testing interval according to clinical risk and the expected speed of change. Document the value, interpretation, action and follow-up plan. After treatment, confirm both biochemical and clinical response and watch for rebound, overcorrection or treatment-related complications.
Communication and handover
Communicate the actual result, units, relevant reference interval, trend and working interpretation. State what has been done, what remains uncertain and which finding should trigger escalation. Avoid vague shorthand when a result has direct implications for medicines, monitoring or level of care.
Frequently asked questions
Can one result establish the diagnosis?
No. Most abnormalities require confirmation, context and a review of trend, symptoms and potential confounders.
Should treatment aim only to normalise the number?
No. Treatment should address the underlying mechanism and improve patient-centred outcomes while avoiding complications of overcorrection.
When should specialist advice be requested?
Seek advice when the abnormality is severe, rapidly changing, unexplained, treatment-resistant, associated with organ dysfunction or outside the population in which the usual pathway is validated.
Key points for practice
- Confirm the result and the clinical context before acting.
- Assess severity, symptoms and rate of change.
- Review medicines, comorbidity and reversible causes.
- Use local protocols and population-specific guidance.
- Trend the response and document a clear follow-up plan.
- Escalate physiological deterioration regardless of a reassuring isolated number.